We recently reported that MICAL2 potentiates breast cancer cell migration via maintaining epithelial growth factor receptor (EGFR) stability, leading to the activation of the P38/HSP27/actin pathway downstream of EGFR (Wang et al., 2018). Here, MICAL2 is linked to breast carcinoma.